osteonecrosis treatment are necessary. A timely overview of the problem, by clearly outlining current knowledge on classification is presented by Steinberg et al. [15] and evidence gaps in hip osteonecrosis treatment is described by Larson et al. [16] .
Risk of collapse and quality of life
Hip osteonecrosis is associated with high hospitalization rates in surgery (around 90% of affected hips) due to a frequent natural evolution to collapse and subsequent hip arthroplasty. Hence, preventing the progression toward collapse is perhaps one of the most important challenges in hip surgery. Occurrence of collapse remains difficult to predict. Radiologic [17] [18] [19] [20] and biologic [21] markers, site of necrosis, volume of osteonecrosis, and etiology of osteonecrosis are discussed in this issue.
Bilateral hip osteonecrosis is a condition that affects the quality of life [22, 23] in patients with osteonecrosis of the femoral head. Males are affected up to three times more than females. This disease is bilateral in 70% of patients who are around 40 years old, i.e., at the maximum of their productive years. Surgery performed on each side may have a deleterious effect on their workforce and subsequently on the economics. This explains that despite favourable results have been reported, osteotomies andz`vascularized grafts [24] are used less frequently in Western countries.
Core decompression and mechanical adjuvant to prevent collapse
Core decompression is the older conservative treatment; however, although core decompression is commonly performed in Western countries, it is seldom performed in Japan and Korea as surgeons are uncertain about the benefits [25] . It is true that the results of core decompression alone are confusing: considering that small lesions do not progress or progress slowly without any intervention and the fact that core decompression shows better outcomes in hips with small early lesions, core decompression alone might be considered sometimes as a treatment that is not so efficient; however, it provides symptomatic relief, and it appears to prevent collapse in early stages. Some authors have associated core decompression to bone substitute or tantalum implants [26] [27] [28] [29] .
Total hip arthroplasty and osteonecrosis
Once collapse has occurred, total hip arthroplasty remains the main treatment. The long-term outcome of implants in these patients is the major concern. Patients with arthroplasty related to osteonecrosis have the reputation to have inferior outcomes compared to those with primary osteoarthritis. These unsatisfactory outcomes can be attributed to the usual patient's young age, but also the associated diseases that are the cause of osteonecrosis as corticosteroids and sickle cell disease. Interestingly, recent reports [30, 31] seem to demonstrate that the risk of revision of arthroplasty in osteonecrosis is not as high as suspected at least during the first 10 years of follow-up. Furthermore, lower rates of revision are noted with systemic lupus erythematosus [32] where a lower level of activity of the patient is probably observed. Most of hip arthroplasties when performed in young people will need revisions and these revisions are associated with bone loss and osteopenia; the quality and quantity of bone stock is a problem in these patients with higher risk of periprosthetic fractures in the long term with associated osteolysis when PE is used as bearing surface. Ceramic-on-ceramic [33] appears to prevent this problem.
Other new technologies as short stems [34, 35] also are now in evaluation in the indication of osteonecrosis to preserve bone stock. Another aspect to consider is that patients may have had some operations before the THA or may have wait a long time before arthroplasty which may in some circumstances worsen the functional result [36] .
Cell therapy and osteonecrosis
Almost three decades ago [37] , it was postulated that bone marrow stem cells (BMSC) could be used to repair the osteonecrosis by Bvirtue^of their unique ability to boost angiogenesis and tissue repair. The pioneering report by Hernigou was the first study suggesting that injection of BMSC in the femoral head was a safe approach able to improve early stages of hip osteonecrosis. Since then, pre-clinical studies and human studies employing unselected BM-derived cells, circulating angiogenic cells, and mesenchymal stem cells have shown that injection of those cells to the femoral head was able to ameliorate hip performance. Andriolo et al. [38] confirm with a systematic review and meta-analysis that regenerative therapies increase survivorship of avascular necrosis of the femoral head, which is confirmed by Hernigou et al. [39] who report a prospective, randomized trial investigating long-term effects of bone marrow cell therapy in patients with bilateral osteonecrosis.
However, after almost 20 years of intensive clinical research in this field, we are still far from having drawn all the conclusions on the indications of cell therapy-based approaches in regenerating hip osteonecrosis. The authors [37, [40] [41] [42] [43] [44] of this issue critically address specific problems-namely cell quality and competence, and microenvironmental changes occurring at the bone osteonecrosis level. BMSC-which are supposed to be Bfunctionally competent^-are often being collected from the BM of patients with bone disease and concomitant risk factors for bone marrow disease (corticosteroids, alcohol abuse…). In other words, we are reinfusing in most cases dysfunctional BMSC in our patients. On the other side, the recipient organ is How can we achieve a permanent correction of maladaptive processes occurred in those cells? Recent work has suggested that BMMSC from some patients may carry significant epigenomic alterations which may substantially alter gene expression trajectories and cell functionality over the life time, regardless of the genetic background. Macro-(lifestyle, pollution, smoking) and microenvironmental stimuli (in situ changes of bone physiology) can explain probably some alterations in the repair. Cell therapy in osteonecrosis has attracted both scientific and public interests as an innovation that could alter the natural history of progression to collapse and to arthroplasty. Therefore, the clinical applications of cell-based therapies in patients with osteonecrosis will continue to be a challenge for patient selection, cell administration, and study design. The cost-effectiveness and the socioeconomic impacts of bone cell therapy in osteonecrosis will also need evaluation, but this will take time (several decades) since this should be compared to the long-term results or arthroplasties with their risk of revision and re-revisions in young patients as explained by the paper of Hernigou et al. [39] . In vitro expanded stem cells could be a solution to increase the number of cells as explained in another paper. But, will healthcare systems be able to afford costs related to procedure standardization, equipped labs for cell isolation and reprogramming, and availability of sophisticated delivery tools?
We conclude by thanking all the authors for taking time to contribute to this special issue on bone osteonecrosis. We apologize for those who submitted papers that were accepted but could not be included in this special issue; their articles will arrive quickly in the following issues of the Journal. We were very honored and privileged to take part in the organization of this special issue. We would like to express our sincere appreciation to Marius Scarlat, Editor in Chief of International Orthopaedics, and his editorial staff for their support for this special issue.
